The Use Of Nicotinic Acid In The Treatment Of Heart Disease

The Use Of Nicotinic Acid In The Treatment Of Heart Disease.
Combining the vitamin niacin with a cholesterol-lowering statin narcotize appears to bid patients no aid and may also snowball side effects, a new on indicates. It's a disappointing result from the largest-ever study of niacin for focus patients, which involved almost 26000 people hgh. In the study, patients who added the B-vitamin to the statin antidepressant Zocor apothegm no added benefit in terms of reductions in heart-related death, non-fatal resolution attack, stroke, or the need for angioplasty or get round surgeries.

The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were charming an inactive placebo, according to a yoke reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. "We are frustrated that these results did not show benefits for our patients," exploration lead author Jane Armitage, a professor at the University of Oxford in England, said in a assembly tidings release medworldplus.net. "Niacin has been used for many years in the belief that it would help patients and foil heart attacks and stroke, but we now know that its adverse faction effects outweigh the benefits when used with current treatments".

Niacin has desire been used to boost levels of "good" HDL cholesterol and cut levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in mobile vulgus at risk for heart disease and stroke. However, niacin also causes a compute of side effects, including flushing of the skin. A narcotic called laropiprant can slash the incidence of flushing in people taking niacin. This unheard of study included patients with narrowing of the arteries.

They received either 2 grams of extended-release niacin benefit 40 milligrams of laropiprant or equivalent placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an mediocre of almost four years.

Besides showing no benevolent purpose on heart health outcomes, the team noted that males and females taking niacin had about the same amount of heart-related events (13,2 percent) as those who took a placebo as an alternative (13,7 percent). Side chattels were common. As already reported online Feb 26, 2013 in the European Heart Journal, by the end of the study, 25 percent of patients bewitching niacin supplementary laropiprant had stopped their treatment, compared with 17 percent of the patients alluring a placebo.

And "The line reason for patients stopping the treatment was because of adverse tangential effects, such as itching, rashes, flushing, indigestion, diarrhea, diabetes and muscle problems," Armitage said at the age in a chronicle news release. "We found that patients allocated to the experiential treatment were four times more likely to stop for skin-related reasons, and twice as probably to stop because of gastrointestinal problems or diabetes-related problems". Patients enchanting niacin and laropiprant had a more than fourfold increased jeopardize of muscle pain or weakness compared to the placebo group, the pair noted.

Did the fault lie with the laropiprant and not niacin? Armitage is doubtful. She piercing to a prior trial, called AIM-HIGH, which was discontinued inopportune in 2011 when researchers found no benefit to niacin treatment. At the time, some experts said that the smaller inhabitants in AIM-HIGH masked any countersign of benefit, but Armitage said the original trial's much bigger study group confirms that niacin possibly does not help.

Speaking in February 2013 at the time of the journal's unfetter of niacin's safety profile, one US expert was less than impressed by niacin's performance. The plague "confirms that, for the now moment, there may be little additional benefit with the use of niacin when patients are well treated with the lipid-lowering statin drugs," said Dr Kevin Marzo, key of cardiology at Winthrop-University Hospital in Mineola, NY. He said that the results of the unique trial, along with those from a previous great study, "now may put the final nail in the coffin on niacin-based strategies to put together HDL and lower cardiovascular events".

Other tried-and-true approaches may realize best, Marzo added. "In combining to statins, our focus should be on continued lifestyle changes such as a Mediterranean diet, complemented with continually exercise," he said. The US Food and Drug Administration had been waiting on the supplementary fling results to decide whether to approve niacin/laropiprant for use against heart disease. But in December 2012, responding to prelude findings, drug maker Merck said it no longer planned to haste for approbation from the FDA and in January 2013

delayed niacin/laropiprant from markets worldwide rxlist box.